Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Milnacipran: Additional Phase III data

Additional data from the Phase III FMS-031 trial showed that 33% and 32% of patients receiving 100 and 200 mg of milnacipran met the composite

Read the full 253 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE